gtx-102
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04259281)
Timeline
Indications
Studied for
Mechanism of action
- Ubiquitin-protein ligase E3AANTISENSE INHIBITOR
UBE3A antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07157254 | Phase 2 | Oct 13, 2025 | Ultragenyx Inc. |
| NCT06617429 | Phase 3 | Dec 31, 2024 | Ultragenyx Inc. |
| NCT06415344 | Phase 3 | Jul 31, 2024 | Ultragenyx Inc. |
| NCT04259281 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | GeneTX Biotherapeutics, LLC, Ultragenyx Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ultragenyx Inc. | For profit | 4 | 3 | 2 | 2020 |
| GeneTX Biotherapeutics, LLC | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1